Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC

Diseases and Conditions Researched

Anus; Colon

What is the purpose of this trial?

To investigate whether PF-05212384 in combination with irinotecan is superior to cetuximab in combination with irinotecan in prolonging PFS in patients with KRAS and NRAS wild type mCRC who have progressed following prior treatment with irinotecan, oxaliplatin, and fluoropyrimidine.


Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Pfizer Inc., U.S. Pharmaceuticals Group
Dates:
Last Updated:
Study HIC#: 1311013076